Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.

Research output: Contribution to journalArticle

Abstract

Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide.

Details

Authors
Organisations
External organisations
  • Memorial Sloan-Kettering Cancer Center
  • Weill Cornell Medical College
  • University of Gothenburg
  • University of Copenhagen
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Urology and Nephrology
Original languageEnglish
JournalEJNMMI Research
Volume6
Issue number1
Publication statusPublished - 2016 Mar 9
Publication categoryResearch
Peer-reviewedYes

Related research output

View all (1)